Abstracts tagged "giant cell arteritis"

Abstract Number: 780 • 2017 ACR/ARHP Annual Meeting
Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice
Lucia C. Domínguez-Casas¹, Javier Loricera¹, Jose L. Hernández², Santos Castañeda³, Vicente Aldasoro⁴, María Varela-García⁵, Rosario Ibañez-Bosch⁵, Antonio Mera⁶, Eva Pérez-Pampin⁶, Alicia Humbría⁷, Jaime Calvo-Alén⁸, Elena Aurrecoechea⁹, Javier Narváez¹⁰, Amalia Sánchez-Andrade¹¹, Paloma Vela¹², Elvira Diez Alvarez¹³, Clara Moriano¹⁴, Cristina Mata¹⁵, Pau Lluch¹⁶, Concepción Moll¹⁷, Íñigo Hernández-Rodríguez¹⁸, Vanesa Calvo-Río¹, José Andrés Román-Ivorra¹⁹, Carlos Vazquez²⁰, Alfonso Corrales¹, MC Gonzalez-Vela²¹, Francisco Ortiz-Sanjuán²², Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Miguel Angel González-Gay²³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁴Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁵Rheumatology, Complejo Hospitalario de Navarra. Navarra. Spain, Navarra, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ⁷Rheumatology, Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁸Rheumatology, Hospital de Sierrallana. Torrelavega. Cantabria. Spain, Alava, Spain, ⁹Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ¹⁰Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ¹¹Hospital Universitario Lucus Augusti. Lugo. Spain, Lugo, Spain, ¹²Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ¹³Complejo Asistencial Universitario de León. León. Spain, León, Spain, ¹⁴Rheumatology, Complejo Asistencial Universitario de León. León. Spain, Leon, Spain, ¹⁵Rheumatology, Hospital de Laredo. Laredo. Spain, Laredo, Spain, ¹⁶Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ¹⁷Rheumatology., Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ¹⁸Rheumatology, CHUVI Vigo. Galicia. Spain, Vigo, Spain, ¹⁹Rheumatology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²¹Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²²Rheumatology., Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ²³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa
Background/Purpose: Randomized clinical trial has shown the efficacy of tocilizumab (TCZ) in Giant cell arteritis (GCA). However this data are of selected cases of clinical…
Abstract Number: 809 • 2017 ACR/ARHP Annual Meeting
Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study
Anthony Sammel¹, Edward Hsiao², Katherine Nguyen³, Geoffrey Schembri², Leslie Schrieber³, Peter Youssef⁴, Beatrice Janssen³ and Rodger Laurent³, ¹Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Royal North Shore Hospital, St Leonards, Australia, ³Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁴Royal Prince Alfred Hospital, Camperdown, Sydney, Australia
Background/Purpose: Positron emission tomography (PET)-CT scan can assess large vessel vasculitis in giant cell arteritis (GCA). It has a reported sensitivity of 80% for biopsy…
Abstract Number: 781 • 2017 ACR/ARHP Annual Meeting
A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis
Valentin S. Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Christina Duftner⁴, Annamaria Iagnocco⁵, George A. W. Bruyn⁶, Greta Carrara⁷, MA D'Agostino⁸, Eugenio De Miguel⁹, Andreas P Diamantopoulos¹⁰, Ulrich Fredberg¹¹, Wolfgang Hartung¹², Alojzija Hočevar¹³, Tanaz A. Kermani¹⁴, Matthew J. Koster¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Møller Døhn¹⁹, Chetan Mukhtyar²⁰, Cristina Ponte²¹, Sofia Ramiro²², Carlo Alberto Scirè²³, Lene Terslev²⁴, Kenneth J. Warrington¹⁵, Bhaskar Dasgupta²⁵ and Wolfgang A. Schmidt²⁶, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁵Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, ⁶Rheumatology, MC Groep, Loenga, Netherlands, ⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ⁸Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ¹⁰Martina Hansens Hospital, Bærum, Oslo, Norway, ¹¹Diagnostic Centre, Silkeborg Regional Hospital, 8600 Silkeborg, Denmark, ¹²Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Rheumatology, University of California Los Angeles, Los Angeles, CA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁷Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁰Norfolk and Norwich University Hospital, Norwich, United Kingdom, ²¹Rheumatology Department, Hospital de Santa Maria - Centro Hospital Lisboa Norte, Lisbon, Portugal, ²²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²³Italian Society for Rheumatology, Milan, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ²⁵Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ²⁶Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: To test the reliability of recently established consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis…
Abstract Number: 810 • 2017 ACR/ARHP Annual Meeting
Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data
Emma Rubenstein¹, Carla Maldini², Solange Gonzalez-Chiappe³, Sylvie Chevret⁴ and Alfred Mahr³, ¹Internal medicine, University Hospital Saint-Louis, Paris, France, ²Rheumatology, Hospital Córdoba, Cordoba, Argentina, ³Internal Medicine, University Hospital Saint-Louis, Paris, France, ⁴Biostatistics, University Hospital Saint-Louis, Paris, France
Background/Purpose: Temporal artery biopsy (TAB) is a reference test for establishing a diagnosis of giant cell arteritis (GCA). A subset of patients with a clinical…
Abstract Number: 782 • 2017 ACR/ARHP Annual Meeting
Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen, Marjolein Hoekstra, Johan Bijzet, Wayel H. Abdulahad, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: GCA and PMR are closely related inflammatory diseases. The diagnostic criteria of both disorders depend on a combination of clinical features and elevated ESR…
Abstract Number: 820 • 2017 ACR/ARHP Annual Meeting
Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis
Peter C. Grayson¹, Sara Alehashemi², Armin Bagheri³, Ali Cahid Civelek⁴, Thomas Cupps⁵, Mariana J. Kaplan⁶, Ashkan Malayeri⁴, Peter A. Merkel⁷, Elaine Novakovich⁸, David A. Bluemke⁴ and Mark Ahlman⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁴Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁵Rheumatology, Georgetown University, Bethesda, MD, ⁶NIAMS/NIH, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, MN, ⁸Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: While several studies have examined the potential of 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) to help establish a diagnosis of large vessel vasculitis (LVV),…
Abstract Number: 783 • 2017 ACR/ARHP Annual Meeting
European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice
Christian Dejaco¹, Sofia Ramiro², Christina Duftner³, Florent L. Besson⁴, Thorsten Bley⁵, Daniel Blockmans⁶, Elisabeth Brouwer⁷, Marco A. Cimmino⁸, Eric Clark⁹, Bhaskar Dasgupta¹⁰, Andreas P Diamantopoulos¹¹, Haner Direskeneli¹², Annamaria Iagnocco¹³, Thorsten Klink⁵, Lorna Neill¹⁴, Cristina Ponte¹⁵, Carlo Salvarani¹⁶, Riemer Slart¹⁷, Madeline Whitlock¹⁸ and Wolfgang A. Schmidt¹⁹, ¹Rheumatology, Hospital of Bruneck, Bruneck, Italy, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁴Department of Nuclear Medicine, CHU Bicêtre, AP-HP, Université Paris-Sud, Paris, France, ⁵University of Würzburg, Würzburg, Germany, ⁶General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁹PMRGCAuk, London, United Kingdom, ¹⁰Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ¹¹Rheumatology, Martina Hansens Hospital, Bærum, Oslo, Norway, ¹²Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ¹³Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, ¹⁴PMRGCAuk, Dundee, United Kingdom, ¹⁵Instituto de Medicina Molecular (IMM), Rheumatology Research Unit, Lisbon, Portugal, ¹⁶Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy, ¹⁷University of Groningen, Enschede, Netherlands, ¹⁸Southend University Hospital, Southend, United Kingdom, ¹⁹Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Modern imaging modalities including ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET/CT) have been increasingly used in primary…
Abstract Number: 823 • 2017 ACR/ARHP Annual Meeting
Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
Paras Karmacharya¹, Dilli Poudel², Pragya Shrestha³, Rashmi Dhital⁴ and Raju Khanal⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Internal Medicine, Reading Health System, WEST READING, PA, ³Internal medicine, Reading Health System, West Reading, PA, ⁴Internal Medicine, Reading Health System, West Reading, PA
Background/Purpose: Most studies looking at seasonal variations in giant cell arteritis (GCA) note a seasonal trend, but show disparity on timing. Concurrent peaks of GCA…
Abstract Number: 786 • 2017 ACR/ARHP Annual Meeting
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
David Brennan¹, Patompong Ungprasert², Kenneth J. Warrington² and Matthew J. Koster², ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. A similar…
Abstract Number: 892 • 2017 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial
Vibeke Strand¹, Sophie Dimonaco², Katie Tuckwell², Micki Klearman³, Neil Collinson² and John H. Stone⁴, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Genentech, South San Francisco, CA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Superior rates of sustained glucocorticoid (GC)–free remission were shown in patients with giant cell arteritis (GCA) treated with weekly (QW) or every-other-week (Q2W) subcutaneous…
Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Alexandra Addario¹, Quitterie Reynaud^2,3, Maxime Samson⁴, Mathilde Francois³, Stéphane Durupt³, Francois Gueyffier¹, Michel Cucherat¹, Isabelle Durieu^2,5 and Jean-Christophe Lega^3,6, ¹Equipe Evaluation et Modélisation des Effets thérapeutiques, Lyon 1 University, Lyon, France, ²HESPER group, Lyon 1 University, Lyon, France, ³Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁴Department of Internal Medicine and Clinical Immunolgy, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal and Vascular, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁶Equipe Evaluation et Modélisation des Effets thérapeutiques, UMR CNR 5558, Lyon 1 University, Lyon, France
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…
Abstract Number: 1734 • 2017 ACR/ARHP Annual Meeting
CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis
Anne-Claire Desbois¹, Valentin Quiniou², Patrick Bruneval³, Nicolas Derian², Anna Maciejewski-Duval², Marlène Garrido⁴, Cloé Comarmond⁵, Jacques Pouchot⁶, Michelle Rosenzwajg², David Klatzmann², Patrice Cacoub⁷ and David Saadoun⁸, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²GHPS, Paris, France, ³HEGP, Paris, France, ⁴I3 laboratory, Pitié-Salpétrière, Paris, France, ⁵DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁶Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ⁷Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁸Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: To compare microarray gene analysis of patients with Giant cell arteritis to patients with Takayasu arteritis. Methods: We performed comparative microarray gene analysis of…
Abstract Number: 790 • 2017 ACR/ARHP Annual Meeting
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Stefania Croci¹, Martina Bonacini¹, Francesco Muratore^2,3, Andrea Caruso³, Antonio Fontana⁴, Luigi Boiardi³, Alessandra Soriano^3,5, Alberto Cavazza⁶, Luca Cimino⁷, Lucia Belloni¹, Maria Parmeggiani¹, Miri Blank^8,9, Yehuda Shoenfeld^8,9 and Carlo Salvarani^2,3, ¹Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ²University of Modena and Reggio Emilia, Italy, Modena, Italy, ³Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁴Unit of Vascular Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁵Campus Bio-Medico, University of Rome, Italy, Roma, Italy, ⁶Unit of Pathology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Unit of Ocular Immunology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁸Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Ramat-Gan, Israel, ⁹Sackler Faculty of Medicine, Tel-Aviv University, Israel, Tel-Aviv, Israel
Background/Purpose: Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which has shown immunomodulatory effects in experimental mouse models of lupus, colitis and arthritis but data in…
Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Jérôme Hadjadj¹, Guillaume Canaud², Tristan Mirault³, Maxime Samson⁴, Patrick Bruneval⁵, Alexis Regent⁶, Claire Goulvestre⁷, Veronique Witko-Sarsat⁸, Nathalie Costedoat-Chalumeau⁹, Loïc Guillevin for the French Vasculitis Study Group¹⁰, Luc Mouthon¹¹ and Benjamin Terrier¹², ¹Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, Paris, France, Paris, France, ²Department of Nephrology and Transplantation, Necker-Enfants Malade, Université Paris Descartes, Sorbonne Paris Cité, INSERM U1151, Necker-Enfants Malades Hospital, Paris, France AP-HP, Paris, France, PARIS, France, ³Department of Vascular Medicine, Georges Pompidou European Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Paris, France, ⁴Dijon University Hospital, Dijon, France, ⁵HEGP, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁷Department of Immunology, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁸Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, LABEX Inflamex, Université Sorbonne Paris Cité, 75013, Paris, France, Paris, France, ⁹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ¹²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…
Abstract Number: 791 • 2017 ACR/ARHP Annual Meeting
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Filippo Crescentini¹, Francesco Muratore², Lucia Spaggiari³, Giulia Pazzola¹, Luigi Boiardi¹, Nicolò Pipitone¹ and Carlo Salvarani⁴, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ³Radiology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy
Background/Purpose: To evaluate aortic diameter and predictors of aortic dilatation using FDG-PET/CT in a longitudinally followed cohort of patients with large vessel vasculitis (LVV) compared…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].